India's molecular diagnostics sector is experiencing significant growth, driven by rapid innovation in testing technologies and increasing investments from venture capitalists. This article explores the market size, emerging trends, key technologies reshaping the landscape, and highlights several innovative Indian startups currently leading this transformative space. We also discuss the role modern laboratory informatics platforms play in supporting these rapidly expanding ventures.

‍

Market Size and Growth Trends

Molecular diagnostics, which involve tests detecting genetic material (DNA or RNA) for accurate disease identification, is one of the fastest-growing segments within India's healthcare industry. In 2024, the Indian molecular diagnostics market was valued at approximately $1.3 billion. It is projected to nearly double to around $2.7 billion by 2033, reflecting an annual growth rate of about 7–8%.

Key factors fueling this robust growth include heightened demand for precise and early disease detection, personalized medicine strategies, and growing awareness about advanced diagnostic technologies. The persistent prevalence of infectious diseases such as tuberculosis, hepatitis, and COVID-19, alongside a rising incidence of genetic disorders and cancer, further accelerates this demand.

The COVID-19 pandemic, in particular, significantly boosted the adoption and development of molecular diagnostics across India. The necessity for reliable and rapid diagnostics during the pandemic led to substantial investment in laboratory infrastructure, enabling molecular testing capabilities to expand rapidly beyond traditional laboratories into hospitals, regional reference centers, and point-of-care settings. This expansion has laid a strong foundation for sustained growth in molecular diagnostics throughout this decade.

‍

Key Technologies Shaping the Molecular Diagnostics Sector in India

Advanced technologies are significantly reshaping molecular diagnostics in India, with four key innovations driving this transformation:

CRISPR-Based Diagnostics: Gene-editing tools like CRISPR have emerged as powerful platforms for highly sensitive disease detection. In 2020, India introduced its first CRISPR diagnostic test named "FELUDA," developed collaboratively by CSIR-IGIB and Tata Group. FELUDA utilizes the CRISPR-Cas9 system to identify SARS-CoV-2 genetic material with accuracy comparable to traditional PCR, but with simpler and more affordable equipment. This groundbreaking test, one of the world's first CRISPR-based diagnostics approved for virus detection, highlights the immense potential of CRISPR for rapid, affordable, and accurate disease screening. Currently, researchers and startups are exploring CRISPR-based solutions for other infectious diseases, including tuberculosis.

‍

Isothermal Amplification (LAMP): Loop-mediated isothermal amplification (LAMP) technology has emerged as a promising PCR alternative, offering rapid DNA amplification at constant temperatures without expensive thermal cycling equipment. Indian startups like OmiX Labs are pioneering this technology with innovations such as the OmiX-iAMP platform, a portable device integrating machine learning for rapid diagnostics of diseases like COVID-19, tuberculosis, and influenza. LAMP-based testing can deliver quick results—often in less than an hour—using basic equipment like heating blocks, significantly broadening access to molecular diagnostics in rural healthcare centers and small clinics across India.

‍

Microfluidic Point-of-Care Systems: Microfluidics has enabled the development of compact, lab-on-chip devices capable of performing complex molecular tests efficiently and portably. Indian innovators like Molbio Diagnostics have made significant strides in this field with the Truenat system, which uses disposable, credit-card-sized PCR chips to perform real-time PCR tests rapidly directly at the patient's location. These battery-operated microfluidic devices drastically reduce turnaround times and can be deployed easily in remote or resource-limited settings, facilitating widespread adoption of molecular diagnostics at point-of-care locations such as primary health centers and airports.

‍

Next-Generation Sequencing (NGS): Next-generation sequencing technologies are rapidly becoming essential for advanced diagnostic applications in India, especially within oncology and genetic testing. NGS allows comprehensive genetic analysis, from targeted cancer gene panels guiding personalized therapies to carrier screening for inherited conditions. The increased adoption of NGS is driven by declining costs, enhanced clinical relevance, and the efforts of leading genomic diagnostics providers like MedGenome, which operates state-of-the-art sequencing facilities. With expanding capabilities in liquid biopsies and rapid pathogen sequencing for epidemiology, NGS is becoming integral to India's shift toward precision medicine and personalized healthcare solutions.

‍

‍

Notable Innovators in Indian Molecular Diagnostics

Several Indian startups have emerged as leaders in the molecular diagnostics space, backed by venture funding and introducing innovative products and services. Below are some notable players, along with their key offerings and funding milestones:​

‍

MedGenome (Bangalore)

Founded in 2013 by Sam Santhosh and Mahesh Pratapneni, MedGenome is a leading genomic diagnostics company in India. It offers over 1,300 genetic tests across oncology, rare inherited diseases, reproductive health, and infectious diseases. MedGenome also operates a direct-to-consumer arm, Genessense, for wellness genetic screening. Its CAP-accredited labs have enabled the company to perform more than 600,000 genetic tests, serving over 5,000 hospitals and 15,000 clinicians in India, with a growing presence in the US, Singapore, and Africa. The company’s comprehensive cancer panels and rare disease genomics services have set industry benchmarks in sensitivity and coverage.​

MedGenome has raised over $185 million in funding to date. Notable investors include Novo Holdings (which led a $50 million round in 2022), LeapFrog Investments, Sofina, Zodius Capital, and IFC. This robust backing has fueled MedGenome’s growth and acquisitions; for example, it acquired diagnostics labs like Prognosis Labs in 2022 and GenX Diagnostics in 2024 to expand its geographic reach. MedGenome’s key differentiators include its large database of Indian genomic variants, addressing the critical genomic data gap in cancer and disease genomics, and its end-to-end capabilities from sample sequencing to bioinformatics. It competes with players like MapmyGenome and Positive Bioscience in bringing advanced genetic testing to the Indian market. ​

‍

Molbio Diagnostics (Goa)

Molbio Diagnostics, based in Verna, Goa, is renowned for its point-of-care molecular testing platform, Truenat. Founded in 2000 alongside its R&D subsidiary Bigtec Labs, Molbio developed Truenat as a portable, battery-powered real-time PCR device for rapid disease diagnosis. The Truenat system can detect over 30 infectious diseases—including tuberculosis, COVID-19, dengue, HIV, and swine flu—and delivers results in under one hour, even in low-resource settings. This innovation made Molbio the first Indian company to bring PCR diagnostics to primary health centers. Notably, in 2020, the World Health Organization endorsed Truenat assays as initial tests for TB detection and rifampicin resistance, validating their high accuracy and suitability for point-of-care use. During the COVID-19 pandemic, Molbio’s platform was widely deployed across India, driving a significant revenue jump in FY2021 as its rapid PCR tests were adopted nationwide. Today, Truenat is used in over 40 countries, and Molbio continues to add new assays and expand globally.​‍

Molbio’s success has attracted significant investment. In 2020, it secured ₹240 crore (approximately $32.5 million) from Motilal Oswal Private Equity to scale manufacturing. In 2022, Singapore’s Temasek invested $85 million, valuing Molbio at $1.6 billion and cementing its unicorn status. This funding is being used to broaden Molbio’s international network, with plans to enter 20–25 new countries annually. The company’s achievements—from WHO endorsement of its TB test to multiple industry awards—underscore its role in revolutionizing infectious disease diagnostics. By bringing high-quality molecular tests to remote areas, Molbio has markedly improved early detection of diseases like TB, earning it a reputation as a global innovator in portable diagnostics.

‍

Mylab Discovery Solutions (Pune)

Pune-based Mylab Discovery Solutions was founded in 2016 by Hasmukh Rawal and Shailendra Kawade with a mission to make advanced diagnostics more accessible and affordable. It focuses on developing high-quality molecular diagnostic kits and automation systems. Mylab gained national prominence in 2020 as the first Indian company to receive regulatory approval for a COVID-19 PCR test kit—the Mylab PathoDetect™ COVID-19 Qualitative PCR kit. The company rapidly scaled the production of these kits during the pandemic, helping bridge India’s testing gap. Beyond COVID-19, Mylab’s flagship product line, PathoDetect, includes kits for detecting various pathogens, such as tuberculosis and foodborne pathogens like E. coli. Mylab also introduced the Compact XL, an automated sample-to-PCR system that streamlines molecular testing workflows for labs. Additionally, it launched PathoCatch, a rapid COVID-19 antigen test, including a home-use version branded as CoviSelf, which contributed to mass screening efforts.​

Mylab has raised significant funding to date. Notably, Serum Institute of India’s CEO Adar Poonawalla and APG Chairman Abhijit Pawar invested in 2020 to boost Mylab’s COVID kit production and expand its molecular diagnostics portfolio. The company has since grown its product range to cover clinical diagnostics, food safety, agriculture, and veterinary testing. By 2021, Mylab’s revenues had skyrocketed due to pandemic-related demand, and although sales normalized post-pandemic, it remains a key player in India’s diagnostics landscape. Mylab’s differentiators include its end-to-end domestic manufacturing, ensuring supply chain independence, and its focus on automation and point-of-care solutions. Its efforts have been pivotal in proving that Indian startups.

‍

MapmyGenome (Hyderabad)

Founded in 2013 by Anu Acharya, MapmyGenome is a pioneering personal genomics company in India. Its flagship product, Genomepatri, offers individuals insights into their genetic predispositions, health risks, traits, drug responses, and ancestry. Customers receive a saliva collection kit, and the analysis is conducted in MapmyGenome’s NABL- and CAP-accredited lab, followed by a detailed report and genetic counseling session. This approach empowers individuals to make informed lifestyle and healthcare decisions. In 2015, MapmyGenome raised a pre-Series A round from investors, including Google India's MD Rajan Anandan and the Singapore Angel Network, totaling approximately $1.1 million. Despite modest funding, the company has established a strong brand presence and expanded its test portfolio to include targeted panels for specific conditions and wellness tests for nutrition and fitness. A key differentiator is its emphasis on end-to-end service, providing not only testing but also in-house genetic counseling to guide customers.

‍

Genes2Me (Gurugram)

Established in 2016 by Neeraj Gupta and Ritu Gupta, Genes2Me has grown into a leading developer and manufacturer of diagnostic kits, offering a spectrum of genetic testing services. The company operates a high-complexity laboratory and has built an extensive portfolio spanning reproductive health, hereditary genetic disease screening, oncology diagnostics, and infectious disease testing. In the preventive care space, it provides personalized DNA wellness tests and carrier screening for couples. In mother-and-child care, it offers non-invasive prenatal testing (NIPT) and newborn genetic screens. In oncology, Genes2Me conducts tumor genomic profiling and liquid biopsy tests and offers at-home cancer risk assessment kits for BRCA gene mutations. During the COVID-19 crisis, the company rapidly developed and supplied RT-PCR test kits, contributing to a revenue spike of ₹150 crore in FY2021. Remarkably, Genes2Me has achieved this growth as a largely bootstrapped venture, with over 100 employees and state-of-the-art ISO/NABL certified labs. Its self-sustained growth has been bolstered by strategic partnerships with hospitals and IVF centers across India, forming B2B ties with doctors to generate test referrals. A notable differentiator is its “bench-to-bedside” approach, emphasizing actionable interpretation and offering clinicians genetic counseling support and treatment guidance based on results. ​

‍

‍

Lilac Insights (Navi Mumbai)

Founded in 2011 by Rakesh Sharma, Subhamoy Dastidar, and Gulshan Bakhtiani, Lilac Insights is a specialized diagnostics company focused on reproductive genetics and cancer genetics. Widely regarded as a pioneer in these niches in India, the company began by offering prenatal screening and neonatal genetic testing services and later expanded into oncology genomics and clinical genetics counseling. Today, Lilac provides a comprehensive menu, including prenatal diagnostics (such as NIPT for chromosomal abnormalities, invasive prenatal tests, and carrier screenings), newborn disorder screening, fertility genetics, and oncology molecular testing (such as tumor mutation panels and hereditary cancer testing). It is also one of the few Indian companies with a dedicated team of certified genetic counselors to support patients and clinicians in understanding test results. Lilac’s laboratories are equipped for cytogenetics, biochemical genetics, and molecular genetics. By 2016, it added oncology gene tests and has since supported oncologists with prognostic and predictive assays for various cancers. This focused expertise has made Lilac Insights a trusted partner for over 500 hospitals and IVF centers across India. The company has raised multiple rounds of funding to fuel its growth, including an early private equity investment in 2017 (₹17.5 crore from IL&FS’s healthcare fund) and an additional ₹50 crore (~$6.9 million) in 2021 from investors including the Allana Group, Rockstud Capital, and Rajiv Dadlani. This funding has been used to scale up its main lab in Navi Mumbai, build regional satellite labs, and enhance its genomic testing facilities. Lilac’s strong brand in the B2B healthcare segment, commitment to providing not just test results but end-to-end clinical interpretation through in-house experts, and bridging obstetricians, oncologists, and the world of genomics have been instrumental in advancing precision medicine in women’s health and oncology in the country. ​

‍

Datar Cancer Genetics (Maharashtra, India)

Founded in the early 2010s by Rajan Datar, Datar Cancer Genetics specializes in non-invasive cancer diagnostics, particularly through liquid biopsy tests. Their flagship platform, TriNetra, utilizes advanced molecular techniques to detect circulating tumor cells (CTCs) and tumor DNA from a simple blood draw. Notably, the TriNetra-Glio test, designed for detecting brain tumors, received the U.S. FDA's Breakthrough Device Designation in January 2023, marking the company's third such designation, following earlier recognitions for their breast and prostate cancer detection assays. Despite operating in an R&D-intensive domain, Datar has raised approximately $809,000 in funding, with investors including Alkemi Growth Capital. The company has also established a CLIA-certified lab in the UK to cater to global clients. ​

‍

4baseCare (Bangalore)

Established in 2018 by Hitesh Goswami and Kshitij Rishi, 4baseCare focuses on precision oncology by leveraging advanced genomics and digital health technology to personalize cancer treatment for Indian patients. Its key offerings include next-generation sequencing (NGS) panels for solid tumors, hereditary cancer risk panels, and an AI-driven clinical decision support platform. A flagship product, TARGT Indiegene™, is a comprehensive genomic profiling kit specifically optimized for South Asian populations, developed by profiling the whole exome and transcriptome from 28 cancer types. In August 2024, 4baseCare secured a $6 million Series A funding round led by Yali Capital, aimed at enhancing product offerings and scaling operations across India and into other Asian markets. The company is also establishing genomics labs in the Philippines, Nepal, and Dubai to expand its footprint in the region. ​ These companies exemplify the innovation and growth within India's molecular diagnostics sector, contributing significantly to personalized healthcare and the broader medical community.

‍

OncoStem Diagnostics (Bangalore)

OncoStem Diagnostics is a Bangalore-based startup (founded in 2011 by Dr. Manjiri Bakre) that specializes in prognostic tests for cancer. Its mission is to personalize cancer treatment planning by predicting the risk of cancer recurrence in patients​. OncoStem’s flagship product, CanAssist Breast, is a proprietary test for early-stage breast cancer patients that stratifies them into low or high risk of cancer recurrence. By analyzing tumor biomarkers (hormone receptor status and a panel of novel protein markers related to tumor progression), CanAssist Breast provides an individualized score indicating the likelihood of the cancer returning after surgery​. This helps oncologists decide whether a patient can safely avoid chemotherapy if their recurrence risk is low, thus sparing patients from unnecessary treatment and side effects​. The test was developed and validated on Indian patient cohorts, making it one of the first such home-grown prognostic tools in Asia. 

OncoStem has also been developing similar risk-stratification tests for other cancers (like oral cancer and ovarian cancer), aiming to extend the personalized treatment approach to more cancer types. OncoStem received early backing from both domestic and international investors. It was seed-funded around 2011–2014, and then in 2017, raised a significant round (Series A) from Sequoia Capital India (now Peak XV) and Artiman Ventures​. Sequoia’s Peak XV profile notes that it “partnered” with OncoStem in 2017​, underscoring that investment. While exact figures aren’t public, the funding allowed OncoStem to complete multi-center clinical validation trials for CanAssist and bring the test to market. A notable differentiator for OncoStem is its focus on the Indian genetic context – many western prognostic tests (like Oncotype DX or MammaPrint) were expensive and validated on western populations.

In contrast, CanAssist Breast was offered at a lower cost and validated on Indian patients, making it more locally relevant. The company has since run thousands of CanAssist tests, and peer-reviewed studies have demonstrated the test’s prognostic utility in guiding therapy. By helping a substantial fraction of patients safely forgo chemotherapy​, OncoStem is improving quality of life and optimizing healthcare costs. Its success is a testament to how Indian startups are innovating in precision medicine, not just in drug discovery but in smart diagnostics that tailor treatment to patient risk.

‍

D-NOME (Hyderabad)

D-NOME is a deep-tech molecular diagnostics startup founded in 2021 by scientists Divya Sriram and Sujoy Deb​. Based in Hyderabad, D-NOME is notable for its novel approach to DNA/RNA amplification – the company is developing the world’s first “device-less” PCR technology​.

Its proprietary platform (dubbed D-LAMP) is a synthetic biology-based, room-temperature amplification system that can perform rapid molecular tests without the need for complex lab equipment​. In essence, D-NOME’s chemistry enables one-step, isothermal amplification of nucleic acids so that even a simple vial can act as a PCR reaction (eliminating expensive thermal cycler machines). This innovation meets the WHO’s ASSURED criteria – Affordable, Sensitive, Specific, User-friendly, Rapid, Equipment-free – for point-of-care diagnostics​. D-NOME’s initial applications target infectious diseases. For example, its assays aim to deliver PCR-level accuracy for diseases like COVID-19 and tuberculosis in a format as easy as a rapid antigen test​. By removing dependence on lab infrastructure and cold-chain, D-NOME’s technology could allow molecular testing to penetrate resource-limited settings (rural clinics, home use, etc.) at a low cost. This breakthrough potential made D-NOME one of the most watched new startups in biotech.

Within two years of its founding, D-NOME had achieved significant milestones. It won the Hello Tomorrow Global Deep Tech Challenge in 2021 and received grants from India’s biotech innovation agencies (BIRAC’s BIG grant, Nidhi-Prayas)​. In early 2023, the startup announced a $1.5 M seed funding round led by Ankur Capital, with participation from 8X Ventures, Campus Fund, 3i Partners, and others​. It was also part of the prestigious Entrepreneur First accelerator and Rebalance incubator, underscoring the confidence in its tech​. D-NOME’s differentiator is clearly its technology: a patent-pending cell-free synthetic biology system enabling PCR amplification at ambient temperature​. If commercialized successfully, it could transform diagnostics in remote areas, allowing rapid tests for diseases like dengue or HIV with just a reagent mix – no electricity or machines required. The company is still in the R&D stage for product development and regulatory approvals, but its early results have been promising. D-NOME exemplifies the new wave of Indian startups that merge biology and engineering with an ambition to “democratize molecular diagnostics” on a global scale​.

‍

‍

HaystackAnalytics (Mumbai)

HaystackAnalytics is a genomics startup founded in 2018 (incubated at IIT Bombay) by Dr. Anirvan Chatterjee, Prof. Kiran Kondabagil, and Gaurav Srivastava​. The Mumbai-based company has built a proprietary SaaS platform that dramatically accelerates genomic data analysis for diagnostic use. Haystack’s claim to fame is reducing the turnaround time for whole genome sequencing analysis from days to mere minutes using its cloud-based pipelines and optimized algorithms​. The startup’s technology enables hospitals and labs to leverage genome sequencing for routine diagnostics without needing in-house bioinformatics teams. 

Haystack’s first major product, launched in mid-2021, applies WGS to tuberculosis: The company introduced a test that sequences the genome of the TB bacterium from patient samples to identify drug resistance mutations, branded as ΩTB (Omega TB) in partnership with LifeCell Diagnostics​. This test can rapidly determine which TB drugs will work for a patient, significantly cutting down the time compared to conventional culture tests. Besides TB, Haystack’s platform has been used for pathogen identification in bloodstream infections and critical care (metagenomic sequencing to pinpoint the causative pathogen), as well as for rare genetic disease diagnosis via whole exome/genome sequencing. Essentially, the startup is productizing genomics for mainstream healthcare by handling the heavy data crunching in the cloud.

HaystackAnalytics has seen early adoption and strategic support. It was part of the Intel Startup Program, leveraging mentorship to optimize its tools on high-performance computing infrastructure​. By 2021, Haystack claimed to power 90% of the genome sequencing-based diagnostic market in India for tests like TB, having partnered with large lab chains, including Thyrocare, Dr. Lal PathLabs, Metropolis, and government hospitals like AIIMS and CMC Vellore​. These partnerships validate its B2B model of enabling established labs to offer genomic tests. Haystack has also secured at least one patent for its pipeline (aimed at making genomic analysis more accessible)​. In terms of funding, the company has been relatively quiet about fundraising; it’s likely supported by grants and angel investors (including IIT-Bombay’s ecosystem). The key differentiator for Haystack is its speed and scalability in genomics – by offering end-to-end automated interpretation, it lowers the barrier for deploying advanced molecular techniques like whole genome sequencing in everyday diagnostics​. As genomic testing moves from niche to necessity (for drug-resistant infections and rare diseases), HaystackAnalytics is positioned as the back-end engine for this revolution in India, essentially turning big genomic data into actionable clinical reports within minutes.

‍

Positive Bioscience (Mumbai)

Positive Bioscience, founded in 2012 by Samarth Jain (along with Bapsy Jain and Meetha Medhora), was one of India’s earliest genomics startups focusing on preventive and personalized medicine​. Headquartered in Mumbai, the company started with a vision of using genetic testing to help people predict and prevent serious diseases. In its early years, Positive Bioscience launched personal genome assessment services similar to 23andMe – customers could get their DNA analyzed for health risks, drug responses, and traits. The company also quickly moved into oncogenomics: it partnered with leading oncology centers (such as Healthcare Global and Medanta Hospital) to provide tumor gene profiling for cancer patients. Positive Bioscience became the Indian channel partner for the US-based sequencing firm Foundation Medicine around 2014, bringing comprehensive cancer genomic test reports (covering hundreds of cancer genes) to oncologists in India. It also introduced a service called OncoDiscover for assessing chemosensitivity and a wellness genetics panel named GenoSnap. By blending software and genetics, Positive built user-friendly reports that interpreted one’s DNA in the context of Indian epidemiology​.

Positive Bioscience garnered high-profile investors during its journey. In 2015, Ratan Tata (Chairman Emeritus of Tata Sons) invested an undisclosed amount in the company, which was seen as a strong endorsement of the importance of personal genomics. It also received funding from MIT’s Ētan Advisors and some angel investors. By the mid-2010s, Positive had grown its footprint, operating genetic counseling clinics in cities like Mumbai and Delhi. A notable achievement was its role in the Tata Trusts Cancer Care initiative: Positive Bioscience was selected to provide genomic testing as part of a government-private effort to advance precision oncology in India. While the company’s profile became a bit lower in recent years (as competition intensified), it is still operational and continues to offer genetic testing services via partnerships with diagnostic labs. Positive’s early-mover advantage and its emphasis on user education helped normalize genomic testing in India. It was among the first to demonstrate that the interpretation of Indian genomes – considering unique genetic variants and lifestyle factors – can yield actionable health insights. In doing so, Positive Bioscience helped lay the groundwork for the now-bustling molecular diagnostics and personal genomics startup ecosystem in India​.

‍

Conclusion: Enabling Scalable Growth with LIMS

As India’s molecular diagnostics ecosystem expands, fast-scaling labs face the challenge of managing increasing sample volumes, complex workflows, and stringent quality requirements. Adopting robust laboratory informatics solutions is becoming essential for these companies to maintain efficiency and regulatory compliance. A modern Laboratory Information Management System (LIMS) can automate sample tracking, data collection, and reporting – streamlining operations from test ordering to result delivery. In this context, platforms like Scispot are emerging as the informatics backbone of choice for ambitious diagnostics labs in India. Scispot’s cloud-based LIMS offers real-time sample management, integration with instruments, and data analytics, empowering labs to handle growth without compromising on accuracy or turnaround times. By leveraging such advanced lab management platforms, India’s molecular diagnostics startups can accelerate innovation, rapidly scale their services, and ultimately reach more patients with life-saving tests – all while ensuring a high standard of laboratory excellence.

‍